Table 1 Clinical feature distributions for number of BMs, BMs progressing post-SRS, and patients (where applicable) for the study sample.
Clinical features | # Patients | # BMs (% progression) |
|---|---|---|
Sex (p = 0.831) | ||
Female | 55 | 66 (21.2%) |
Male | 44 | 57 (22.8%) |
Age (p = 0.925) | ||
Median (range) | 58.0 (38.4–86.0) years | |
Primary cancer active (p = 0.002) | ||
Yes | 44 | 55 (9.1%) |
No | 55 | 68 (32.4%) |
Primary cancer site (p = 0.003) | ||
Lung | 59 | 70 (12.9%) |
Breast | 10 | 14 (35.7%) |
Renal | 10 | 15 (13.3%) |
Colorectal | 8 | 10 (40.0%) |
Skin | 8 | 9 (66.7%) |
Other | 4 | 5 (20.0%) |
Primary cancer histology (p = 0.001) | ||
Adenocarcinoma | 49 | 65 (20.0%) |
NSCLC | 31 | 36 (11.1%) |
Melanoma | 8 | 9 (66.7%) |
Squamous carcinoma | 7 | 8 (50.0%) |
Other | 4 | 5 (0.0%) |
Extracranial systemic metastases (p = 0.665) | ||
Yes | 39 | 50 (20.0%) |
No | 60 | 73 (23.3%) |
Systemic therapy status (p = 0.033) | ||
Radical | 51 | 10 (20.0%) |
Palliative | 41 | 60 (31.7%) |
None | 7 | 53 (11.3%) |
Neurological symptoms steroid response (p = 0.426) | ||
Fully resolved | 48 | 31 (16.1%) |
Improvement | 7 | 4 (50.0%) |
Limited improvement | 4 | 56 (25.0%) |
No improvement | 26 | 11 (9.1%) |
Unknown | 14 | 21 (23.8%) |
ECOG/WHO performance score (p = 0.580) | ||
0 | 31 | 39 (17.9%) |
1 | 60 | 73 (21.9%) |
2 | 6 | 9 (33.3%) |
3 | 2 | 2 (50.0%) |
GTV volume (p < 0.001) | ||
Median (range) | 3.07 (0.02–30.23) cc | |
< 7.5 cc | – | 94 (17.0%) |
> 7.5 cc | – | 29 (37.9%) |
BM location (p = 0.626) | ||
Supratentorial | – | 96 (22.9%) |
Infratentorial | – | 27 (18.5%) |
SRS prescription (p = 0.003) | ||
15 Gy in 1 fraction | – | 5 (0.0%) |
18 Gy in 1 fraction | – | 36 (30.6%) |
21 Gy in 1 fraction | – | 72 (13.9%) |
24 Gy in 3 fractions | – | 10 (60.0%) |
